Louisville, KY, June 12, 2017 -- Appriss Health, provider of the most comprehensive platform for substance use disorder in the U.S., today announced it has recently signed an agreement with the Arizona Board of Pharmacy to enable integration of controlled substance prescription information into electronic health records (EHRs) and pharmacy management systems statewide. The solution, PMP Gateway, can enable access to data, analytics, insight, tools and resources from prescription drug monitoring programs (PDMPs) within care team workflows in real-time, at the point-of-care to improve patient safety and outcomes.
|
|||
PMP Gateway is a technology that provides a variety of options for health IT systems to integrate PDMP information and functionality into prescriber and pharmacist workflows. Prior to PMP Gateway, prescribers and pharmacists had to log into separate websites to retrieve a patient's prescriptions and then cross-reference this data with a patient's health information in other systems. The PMP Gateway solution provides instant access to the patient's prescription drug information and associated insights and resources within the EHR and pharmacy dispensing system.
This announcement follows a January implementation in Arizona of Appriss Health’s PMP AWARxE prescription monitoring program solution, which will include expanded features such as enhanced prescriber reports, advanced analytics and an integration with state licensing board databases that will streamline the PMP registration process. PMP AWARxE allows pharmacies to fulfill mandatory controlled substance dispensation reporting requirements and offers secure accessibility to data across state lines. Appriss Health’s PDMP solutions are currently live in 42 states and municipalities.
Arizona is now the third state committed to implement a statewide, enterprise license for in-workflow PDMP integration. These enhancements to the state PDMP will position Arizona to continue a successful implementation of State Senate Bill 1283, which will require medical practitioners to request a patient prescription history prior to prescribing certain controlled substances, including opioids.
“We want to recognize Appriss Health as our trusted partner in helping to enact the mission of the Arizona State Board of Pharmacy – to protect the health, safety and welfare of the citizens of Arizona,” said Kam Gandhi, PharmD, Executive Director, Arizona State Board of Pharmacy. “By providing prescription drug information instantly, at the time and place of patient care, we expect to see an increase in information usage to improve patient safety and outcomes while we simultaneously work to continue to combat prescription drug addiction, overdose and death in Arizona.”
The benefits of EHR integration into state PDMPs have been widely-recognized as beneficial to improving patient safety, mitigating drug diversion and ensuring compliance.
“Arizona is truly on the forefront in addressing substance use disorder,” said Rob Cohen, President, Appriss Health. “We want to thank the Arizona Board of Pharmacy for recognizing the need to take immediate action to address the growing, nationwide problems associated with prescription drug addiction and abuse by empowering all of their physicians and pharmacists statewide with the right information they need, right at their fingertips, to make better decisions about prescribing and dispensing controlled substances.”
About Appriss Health
Appriss Health provides the nation's most comprehensive platform for early identification, prevention and management of substance use disorder (SUD). We provide state government agencies with the most advanced repository of controlled substance dispensing data, and deliver real-time clinical decisioning support, critical insights and interventions to physicians, pharmacists, and care team members through millions of patient encounters each year. Our solutions enable healthcare providers, pharmacists and care team members to assess and manage clinical risk in order to positively impact patient safety and population health outcomes. For more information, please visit www.apprisshealth.com.
Attachments:
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/ec53a1df-3ea7-48d4-92a1-e7432fa6b45f
David Griffin Appriss Health 5028153880 [email protected]


Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions
OpenAI Addresses Security Vulnerability in macOS App Certification Process
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started 



